Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4

Journal of Virology

Volumn 78, Issue 21, 2004, Pages 12022-12029

  Owen, Andrew ^a   Chandler, Becky ^a   Bray, Patrick G ^b   Ward, Stephen A ^b   Hart, C Anthony ^a   Back, David J ^a   Khoo, Saye H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN P;

ARTICLE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FLOW CYTOMETRY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROSCOPY, CONFOCAL; P-GLYCOPROTEIN; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, MESSENGER; VIRUS REPLICATION;

EID: 6344294111     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.21.12022-12029.2004     Document Type: Article

References (48)

1. Agrati, C., F. Poccia, S. Topino, P. Narciso, C. Selva, L. P. Pucillo, G. D'Offizi, G. Antonelli, F. Bellomi, O. Turriziani, and F. Bambacioni. 2003. P-glycoprotein expression by peripheral blood mononuclear cells from human immunodeficiency virus-infected patients is independent from response to highly active antiretroviral therapy. Clin. Diagn. Lab. Immunol. 10:191-192.
2. Aszalos, A., K. Thompson, J. J. Yin, and D. D. Ross. 1999. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp). Anticancer Res. 19:1053-1064.
3. Berger, E. A. 1998. HIV entry and tropism. When one receptor is not enough. Adv. Exp. Med. Biol. 452:151-157.
4. Brumme, Z. L., W. W. Dong, K. J. Chan, R. S. Hogg, J. S. Montaner, M. V. O'Shaughnessy, and P. R. Harrigan. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201-208.
5. Chandler, B., L. Almond, J. Ford, A. Owen, P. Hoggard, S. Khoo, and D. Back. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. J. Acquir. Immune Defic. Syndr. 33:551-556.
6. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
7. Dragic, T. 2001. An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82:1807-1814.
8. Eagling, V. A., H. Wiltshire, I. W. Whitcombe, and D. J. Back. 2002. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17.
9. Fellay, J., C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, and A. Telenti. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
10. Ford, J., P. G. Hoggard, A. Owen, S. H. Khoo, and D. J. Back. 2003. A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J. Immunol. Methods 274:129-137.
11. Germann, U. A., P. J. Ford, D. Shlyakhter, V. S. Mason, and M. W. Harding. 1997. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141-155.
12. Grivel, J. C., M. L. Penn, D. A. Eckstein, B. Schramm, R. F. Speck, N. W. Abbey, B. Herndier, L. Margolis, and M. A. Goldsmith. 2000. Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue. J. Virol. 74:5347-5351.
13. Helbig, G., K. W. Christopherson II, P. Bhat-Nakshatri, S. Kumar, H. Kishimoto, K. D. Miller, H. E. Broxmeyer, and H. Nakshatri. 2003. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278:21631-21638.
14. + natural killer cells. Pharmacogenetics 11:293-298.
15. Huisman, M. T., J. W. Smit, H. R. Wiltshire, R. M. Hoetelmans, J. H. Beijnen, and A. H. Schinkel. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59:806-813.
16. Ifergan, I., N. F. Bernard, J. Bruneau, M. Alary, C. M. Tsoukas, and M. Roger. 2002. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 16:2340-2342.
17. Inaba, T., N. E. Fischer, D. S. Riddick, D. J. Stewart, and T. Hidaka. 1997. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. 93:215-219.
18. Johnston, E. R., L. S. Zijenah, S. Mutetwa, R. Kantor, C. Kittinunvorakoon, and D. A. Katzenstein. 2003. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J. Virol. 77:7682-7688.
19. Jones, P. M., and A. M. George. 2000. Symmetry and structure in P-glycoprotein and ABC transporters: what goes around comes around. Eur. J. Biochem. 267:5298-5305.
20. + cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
21. Kreisberg, J. F., D. Kwa, B. Schramm, V. Trautner, R. Connor, H. Schuitemaker, J. I. Mullins, A. B. van't Wout, and M. A. Goldsmith. 2001. Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J. Virol. 75:8842-8847.
22. Lee, C. G., M. Ramachandra, K. T. Jeang, M. A. Martin, I. Pastan, and M. M. Gottesman. 2000. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 14:516-522.
23. Manes, S., G. del Real, R. A. Lacalle, P. Lucas, C. Gomez-Mouton, S. Sanchez-Palomino, R. Delgado, J. Alcami, E. Mira, and A. C. Martinez. 2000. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1:190-196.
24. Manetti, R., L. Cosmi, G. Galli, F. Annunziato, M. Mazzetti, S. Romagnani, and E. Maggi. 2000. Enhanced expression of the CXCR4 co-receptor in HIV-1-infected individuals correlates with the emergence of syncytia-inducing strains. Cytokines Cell Mol. Ther. 6:19-24.
25. Mistry, P., A. J. Stewart, W. Dangerfield, S. Okiji, C. Liddle, D. Bootle, J. A. Plumb, D. Templeton, and P. Charlton. 2001. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 61:749-758.
26. Nasi, M., V. Borghi, M. Pinti, C. Bellodi, E. Lugli, S. Maffei, L. Troiano, L. Richeldi, C. Mussini, R. Esposito, and A. Cossarizza. 2003. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-1698.
27. Owen, A., B. Chandler, J. Ford, S. H. Khoo, and D. J. Back. 2003. Differential expression of HIV co-receptors between CEM, CEMVBL and CEME1000 cells. J. Infect. Dis. 187:874-876.
28. + T cell depletion in HIV-1-infected human lymphoid tissue. Proc. Natl. Acad. Sci. USA 96:663-668.
29. Perry, C. M., and S. Noble. 1998. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
30. Pierdominici, M., A. Giovannetti, F. Ensoli, F. Mazzetta, M. Marziali, M. R. De Cristofaro, D. Santini-Muratori, W. Leti, and F. Aiuti. 2002. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 29:122-131.
31. Profit, L., V. A. Eagling, and D. J. Back. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
32. Raviv, Y., A. Puri, and R. Blumenthal. 2000. P-glycoprotein- overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane. FASEB J. 14:511-515.
33. Scarlatti, G., E. Tresoldi, A. Bjorndal, R. Fredriksson, C. Colognesi, H. K. Deng, M. S. Malnati, A. Plebani, A. G. Siccardi, D. R. Littman, E. M. Fenyo, and P. Lusso. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3:1259-1265.
34. Schramm, B., M. L. Penn, R. F. Speck, S. Y. Chan, E. De Clercq, D. Schols, R. I. Connor, and M. A. Goldsmith. 2000. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. J. Virol. 74:184-192.
35. Schuitemaker, H., M. Root, N. A. Kootstra, M. W. Dercksen, R. E. de Goede, R. P. van Steenwijk, J. M. Lange, J. K. Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
36. Simmons, G., D. Wilkinson, J. D. Reeves, M. T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P. W. Gray, R. A. Weiss, and P. R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic, and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
37. Speck, R. R., X. F. Yu, J. Hildreth, and C. Flexner. 2002. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J. Infect. Dis. 186:332-340.
38. Spijkerman, I., F. de Wolf, M. Langendem, H. Schuitemaker, and R. Coutinho. 1998. Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J. Infect. Dis. 178:397-403.
39. Srinivas, R. V., D. Middlemas, P. Flynn, and A. Fridland. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 42: 3157-3162.
40. Steele, A. D., E. E. Henderson, and T. J. Rogers. 2003. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309: 99-107.
41. Walz, G., B. Zanker, C. Barth, K. J. Wieder, S. C. Clark, and T. B. Strom. 1990. Transcriptional modulation of human IL-6 gene expression by verapamil. J. Immunol. 144:4242-4248.
42. Xiao, L., D. L. Rudolph, S. M. Owen, T. J. Spira, and R. B. Lal. 1998. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 12:F137-F143.
43. Yamaguchi, M., M. Kuzume, H. Nakano, and K. Kumada. 1998. Verapamil suppressed lymphocyte adhesion to vascular endothelial cells via selective inhibition of VCAM-1 expression. Transplant. Proc. 30:2955.
44. Yamaguchi, M., H. Suwa, M. Miyasaka, and K. Kumada. 1997. Selective inhibition of vascular cell adhesion molecule-1 expression by verapamil in human vascular endothelial cells. Transplantation 63:759-764.
45. Zanker, B., G. Walz, K. J. Wieder, M. Moscovitch-Lopatin, B. R. Smith, and T. B. Strom. 1989. Verapamil selectively inhibits expression of interleukin-2 messenger RNA in mitogen activated mononuclear blood cells. Transplant. Proc. 21:85-87.
46. Zhang, Y., B. Lou, R. B. Lal, A. Gettie, P. A. Marx, and J. P. Moore. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910.
47. Zhang, Y. J., T. Dragic, Y. Cao, L. Kostrikis, D. S. Kwon, D. R. Littman, V. N. KewalRamani, and J. P. Moore. 1998. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72:9337-9344.
48. Zhang, Y. J., and J. P. Moore. 1999. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J. Virol. 73:3443-3448.